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Abstract 40 
Long-term treatment with Proton Pump Inhibitors (PPIs) is associated with an increased risk of 41 
fractures in the general population. PPIs are widely prescribed to dialysis patients but to date no study 42 
specifically tested, by state-of-art statistical methods, the relationship between PPIs use and fractures 43 
in this patient-population. This study aimed to assess whether PPIs use is associated with bone 44 
fractures (i.e. hip fractures and fractures other than hip fractures) in a large international cohort of 45 
hemodialysis patients. We considered an observational prospective cohort of 27097 hemodialysis 46 
patients from the DOPPS study. Data analysis was performed by the Fine & Gray method, considering 47 
the competitive risk of mortality, as well as by a cause-specific hazards Cox model dealing death as 48 
a censoring event and matching patients according to the prescription time. Out of 27,097 49 
hemodialysis patients, 13,283 patients (49%) were on PPI treatment. Across the follow-up (median:19 50 
months), 3.8 bone fractures x 100 person-years and 1.2 hip fractures x 100 person-years occurred. In 51 
multiple Cox models, considering the competitive risk of mortality, the incidence rate of bone (SHR: 52 
1.22, 95% CI: 1.10-1.36, P<0.001) and hip fractures (SHR: 1.35, 95% CI: 1.13-1.62, P=0.001) was 53 
significantly higher in PPI treated than in PPI untreated patients. These findings held true also in 54 
multiple, cause-specific, hazards Cox models matching patients according to the prescription time 55 
(bone fractures, HR: 1.47, 95% CI: 1.23-1.76, P<0.001, hip fractures (HR: 1.85, 95% CI: 1.37-2.50, 56 
P<0.001). The use of PPIs requires caution and a careful evaluation of risks/benefits ratio in 57 
hemodialysis patients. 58 
 59 
  60 
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Introduction 61 
Proton pump inhibitors (PPIs) are commonly prescribed for gastrointestinal disorders, in 62 
which the inhibition of gastric acid secretion is desirable, such as peptic ulcer disease, dyspepsia and 63 
gastroesophageal reflux disease. The use of PPIs is widespread and has progressively increased since 64 
their introduction.1 In the ambulatory setting the prevalence of visits in which patients used PPIs 65 
increased from 4.0% in 2002 to 9.2% in 2009.2 Moreover, 63% of the patients using PPIs did not 66 
have gastrointestinal complaints or a specific indication for PPI use. Accordingly, PPIs were included 67 
among the most common potentially inappropriate medications, identified using the updated Beers 68 
criteria. 3 For this reason, while prescribing this class of drugs, an accurate evaluation of the 69 
risks/benefits ratio of long term use of PPI is formally recommended by the American 70 
Gastroenterological Association.4 In a Danish nationwide study, the prevalence of PPI use in adults 71 
increased from 2% in 2002 to 7.4% in 2014 and prolonged treatment was very common.5 Remarkably, 72 
PPI use increased with age, its prevalence among patients over 60 years old reaching 14.0% in men 73 
and 16.3% in women and exceeding 20% among patients aged 80 years and over.5 In stage 5D chronic 74 
kidney disease (CKD) patients, we found that PPI use is even higher, with 76 % of patients receiving 75 
long-term treatment.6 Bone and mineral disorders, including secondary hyperparathyroidism and 76 
bone fractures, are more common among CKD patients than in people with normal renal function.7 77 
In the general population, PPI use is associated with an increased risk of fractures.8,9 78 
The aim of this study was to assess the relationship between use of PPIs, and bone and hip 79 
fractures in hemodialysis patients of the phases 2-4 of the observational Dialysis Outcomes and 80 
Practice Patterns Study (DOPPS) study, which included the systematic collection of fractures 81 
requiring hospitalization. 82 
Material and Methods 83 
Patient population  84 
The DOPPS is a prospective cohort study of hemodialysis practices based on the collection of 85 
observational longitudinal data for a random sample of patients from dialysis facilities in a 86 
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representative and random sample of units in more than twenty countries.7 DOPPS 1 began in 1996-87 
2001 in the United States, in 1998–2001 in Europe (France, Germany, Italy, Spain, and the United 88 
Kingdom) and in 1999-2001 Japan. DOPPS 2 (2002–2004), 3 (2005–2008), and 4 (2009–2011), 89 
included the same DOPPS 1 countries, plus Australia, New Zealand, Canada, Belgium, and Sweden. 90 
The DOPPS phases 2-4 included 34593 hemodialysis patients, of whom 27857 (i.e. 81%) were 91 
hospitalized for various reasons.  92 
Study groups, outcome and exposure definition 93 
From a source population of 27857 hospitalized patients, 75 were excluded because of missing 94 
baseline demographic characteristics (such as age, race, time of starting dialysis and gender) and 685 95 
patients were excluded because of missing information on PPI treatment. Thus, 27097 hospitalized 96 
patients were available for the present analysis. We specifically focused on hospitalized patients to 97 
better capture medication data thus minimizing the possibility of information bias. 98 
The DOPPS investigators identified all first hospitalizations (defined by an overnight hospital 99 
stay) with an associated “bone fracture diagnosis code” according to international standards for 100 
hospital admissions. Bone fractures were coded as either 'hip' or 'other'; information on other types 101 
of fractures (e.g. vertebral fractures) were not available. Thus, bone fractures include “hip-fractures” 102 
and fractures other than hip fractures. Hospitalizations and outpatient visits (including fracture-related 103 
visits) occurring during the study, along with diagnoses and procedures (i.e. X-ray imaging) relevant 104 
to the hospitalization or outpatient visit, were reported chronologically for each patient. Capturing 105 
both hospitalization events and outpatient visits provided a reasonable expectation that the vast 106 
majority of fracture-related events were recorded in this study. Hip fractures were distinguishable 107 
from among all reported fracture-related events, whereas fracture types other than hip fracture were 108 
less well defined and consequently analysed collectively. For fracture event rates, follow-up 109 
continued until the first of death, fracture hospitalization, transplantation, renal replacement therapy 110 
modality switch, recovery of renal function, departure from the facility, or end of follow-up. PPI use 111 
was assessed on individual basis, i.e. whether or not the PPI was administered in the patient concerned 112 
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at the time of the visit.  Prevalent PPI users were those who were already treated with the drug at the 113 
date of enrolment. Naïve users or “new users” were those who start the treatment after the enrolment 114 
into the study.  115 
Statistical Analysis 116 
Patients’ characteristics were summarized as mean ± standard deviation, median and inter-117 
quartile range or as percent frequency, and comparisons between patients’ groups were made by 118 
independent T-Test, Mann-Whitney Test or Chi Square Test, as appropriate.  The frequency of bone 119 
and hip fractures requiring hospitalization across Countries was expressed as incidence rate 120 
(fractures/100 person-years) and 95% confidence interval. In the ‘time to the first event’ survival 121 
analyses, the index date for naïve PPI users was the date of starting treatment whereas for prevalent 122 
PPI users and nonusers the index date was the date of enrollment. 123 
The crude and adjusted relationships between PPI treatment and incidence rate of bone and 124 
hip fractures, taking into account the competitive risk of mortality, were investigated by using the 125 
cumulative incidence function and the Fine and Gray approach,10 respectively. The effect of PPI on 126 
study outcomes was also investigated by a cause-specific hazards Cox model dealing patient death as 127 
a censoring event and stratifying by Country and study phase. To provide further insight into the 128 
pathophysiological implications of study results, we calculated the etiological fraction or attributable 129 
risk (AR), i.e. the proportion of fractures that would be prevented in our study cohort if the PPI 130 
treatment was eliminated in treated patients. 131 
In multiple Cox models, we included PPI treatment as well as a series of potential confounders 132 
(i.e. all variables listed in Table 1): age, gender, race, BMI, diabetes, smoking (past and current), 133 
background CV comorbidities, dialysis vintage (i.e. the time spanning from the date of dialysis 134 
initiation to the date of enrolment into the study), concomitant treatments (any form of Vitamin D, 135 
phosphate binders, and calcium-based phosphate binders), and biochemical data [albumin, PTH, 136 
calcium, phosphate, alkaline phosphatase and fractional urea clearance (Kt/V)].  To account for 137 
prevalent users bias, a sensitivity analysis on naive patients versus no users was also performed. 138 
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Concomitant therapies (any form of Vitamin D, phosphate binders, and calcium-based phosphate 139 
binders) were defined differentially for the two study outcomes, depending on the fact whether the 140 
date of each specific treatment start precedes or not the date of the outcome occurrence. 141 
Missing values for confounding variables were imputed by multiple imputation in which 30 142 
completed data sets were generated and analyzed with standard combination rules for multiple 143 
imputation. Each variable was used as a confounder in the imputation model. In Cox models fitted 144 
according to the Fine and Gray approach, data were expressed as sub-distribution hazard ratios 145 
(SHR), 95% CIs and P values. In cause-specific hazards Cox models dealing patient death as a 146 
censoring event, stratifying by Country and study phase and matching patients of the two arms 147 
according to the prescription time-distribution,11 data were expressed as hazard ratios (HR), 95% CIs 148 
and P values. 149 
All analyses were performed by two standard statistical packages (SPSS for Windows Version 150 
22, IBM, USA; STATA/IC 13.0 StataCorp P, TX, USA). 151 
Role of the Funding source 152 
None of the authors received any funding for this study.  153 
Patient and Public Involvement 154 
Full details about the involvement of patients and public in the DOPPS data collection are given 155 
elsewhere (see https://www.dopps.org/). 156 
Results 157 
The main demographic, clinical and biochemical data of the whole study population 158 
(n=27,097) as well as of PPI treated (n=13,283, 49%) and untreated (n=13,814, 51%) patients are 159 
given in Table 1.  In individual countries, the prevalence of PPI treated patients ranges widely from 160 
28.6% in Japan to 73.5% in Spain (Supplementary Figure 1). Overall, patients from western 161 
countries represent 77% of the PPI treated population and 60% of the non-PPI treated patients, while 162 
the corresponding data for Asians are 12% and 28%. The incidence rates of bone fractures were higher 163 
on average in PPI treated than in PPI untreated patients in all countries but Italy and Germany 164 
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(Supplementary Figure 2).  However, in Italy hip fractures were higher in PPI treated than in 165 
untreated patients whereas in Germany the contrary was observed. 166 
Across the follow-up period (median 19 months, IQR: 10-28 months), 1,592 patients 167 
experienced bone fractures (3.8 bone fractures/100 person-years, 95% CI: 3.6-3.9) and 528 patients 168 
had hip fractures (1.2 hip fractures/100 person-years, 95% CI: 1.1-1.3). Overall, 6,249 patients died. 169 
The mortality rate was higher in PPI users than in no users (25.8% versus 20.4%, P<0.001) raising a 170 
problem of competitive risks. In crude Cox models (Fine & Gray approach) taking into account the 171 
competitive risk of mortality, the incidence rate of bone (SHR: 1.36, 95% CI: 1.24-1.51, P<0.001) 172 
and hip fractures (SHR: 1.70, 95% CI: 1.43-2.02, P<0.001) was significantly higher in PPI treated 173 
than in PPI untreated patients (Figure 1-upper panels). A sensitivity analysis in naïve PPI users 174 
(Supplementary Table I), confirmed a higher incidence rate of bone and hip fractures in PPI treated 175 
than in PPI untreated patients (Figure 1-bottom panels). The calculation of the attributable risk (AR) 176 
showed an AR of 30% for bone fractures and 44% for hip fractures in the whole study population and 177 
an AR of 37% and 52%, respectively, in the sensitivity analysis on naïve users versus untreated 178 
suggesting that about one half of hip fractures and more than one third of bone fractures could be 179 
avoided if PPI use was eliminated in treated patients. Data adjustment for potential confounders, i.e. 180 
for all variables listed in Table 1, did not materially affect the PPI-study outcomes links either in the 181 
whole study cohort (‘prevalent users + naïve users’ versus ‘no users’, see Table 2) or in a sensitivity 182 
analysis assessing the fractures risk of ‘naïve users versus no users’ (Table 3).   183 
In multiple, country and phase stratified, cause-specific hazards Cox models (adjusting for the 184 
same set of variables listed in Tables 2-3) in patients of the two arms matched according to the 185 
prescription time (n=14136 of whom 3276 treated with PPI and 10860 untreated), PPI treatment 186 
confirmed as a strong and independent risk factor of study outcomes [bone fractures, HR Country and 187 
phase stratified: 1.47, 95% CI: 1.23-1.76, P<0.001; hip fractures, HR Country and phase stratified: 1.85, 95% CI: 188 
1.37-2.50, P<0.001]. Of note, diabetes consistently emerged as a strong risk factor of bone and hip 189 
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fractures in the study population (see Tables 2-3) independently of PPI use and other potential 190 
confounders. 191 
Discussion 192 
In a large, international cohort of hospitalized hemodialysis patients, the use of PPI associates 193 
with an increased risk of bone and hip fractures independently of the competitive risk of mortality 194 
and potential confounders including demographic, clinical and biochemical data as well as 195 
concomitant therapies. Thus, the study provides evidence supporting the notion that PPI use is a risk 196 
factor of bone and hip fractures in the dialysis population.  197 
PPIs are among the most widely prescribed medications worldwide. The average prevalence 198 
of PPI use in the DOPPS population is 49%, a figure markedly higher than that in the general 199 
population,6 where several studies have highlighted the association between PPI treatment and bone 200 
fractures.8,9,12 In a meta-analysis including 11 observational studies,12 the reported relative risk for 201 
hip fractures associated with PPI use was 1.30 (95 % CI: 1.19-1.43) and such an association was of 202 
similar magnitude of that we found in the whole dialysis population comparing prevalent + naïve 203 
users versus no users (SHR: 1.35, 95% CI: 1.13-1.62- Table 2) but lower than that emerged in the 204 
sensitivity analysis comparing naïve users versus no users (SHR: 1.62, 95% CI: 1.24-2.11) indicating 205 
that the prevalent users bias should be taken into account when investigating the effect of PPI on 206 
adverse clinical outcomes in hemodialysis patients. In the same metanalysis,12 the relative risk 207 
associated with PPI users was also increased for spine (RR: 1.56, 95% CI 1.31–1.85) and any-site 208 
fractures (RR: 1.16, 95% CI 1.04–1.30).  Based on growing and compelling evidences reported in 209 
literature, the FDA issued a drug safety communication warning about the possibility of increased 210 
risk of fractures of the hip, wrist, and spine with the long-term use of both prescription and over-the-211 
counter PPIs in the general population.13 This recommendation is of obvious public health importance 212 
because fractures per se are not only disabling clinical events but also a risk factor of mortality. 213 
Indeed, a population-based study highlighted a relationship between bone fractures and an increased 214 
risk of death and reported a mortality rate of 20% in the first year after a hip fracture.14 Similar data 215 
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on mortality associated with hip fractures were also reported in hemodialysis patients: post-fracture 216 
mortality rates exceeded 500/1000 patient years and fractured patients had higher unadjusted rates of 217 
death (3.7-fold) than the overall non-fractured dialysis population.7 On the other hand, mortality is 218 
exceedingly higher in hemodialysis patients than in the general population and for this reason it could 219 
act as a competitive risk while investigating the relationship between PPI use and bone fractures.  220 
Remarkably, in our study the relationship between PPI use and bone fractures remained significant 221 
also considering the competitive risk of death for both bone and hip fractures, either on univariate or 222 
on multivariable Cox analyses.    223 
Mechanisms linking PPI use and bone fractures are still poorly understood, but there are 224 
several potentially plausible explanations. Importantly, fractures may be facilitated not only by 225 
reduction in bone density, but also by derangement of bone quality, and both bone quantity and quality 226 
could be affected by PPI use. Inhibition of gastric acid secretion can adversely affect the absorption 227 
of several nutrients, vitamins and drugs.15 A reduced intestinal absorption of calcium and magnesium 228 
could lead to osteoporosis and fractures.  However, in our study blood biochemistry results did not 229 
affect the association between PPI and fractures. Our results are consistent with accurate metabolic 230 
studies showing that PPI-associated hypochlorhydria does not decrease fractional calcium absorption 231 
following 30 days of continuous PPI use.16 Although we did not measure magnesium level in the 232 
study cohort, the homeostasis of this cation seems to be crucial for bone health.  Magnesium 233 
deficiency, a well known adverse effect of PPI use,17 contributes to bone impairment, both directly 234 
by acting on crystal formation and on bone cells, and indirectly by interfering with the activity of 235 
parathyroid hormone and 1,25(OH)2-vitamin D synthesis, as well as by promoting low grade 236 
inflammation.18 Magnesium is also deposited in large quantities in bone, being essential for bone 237 
health. In addition, since magnesium is acting as inhibitor of extra-skeletal calcification, PPI-induced 238 
hypomagnesemia may worsen vascular calcifications in patients with CKD.19 Interestingly, in the 239 
DOPPS cohort treated with PPIs peripheral artery disease was more common (34% of patients) 240 
compared to untreated patients (26%).  Proton pump inhibitors interfere with the active transport of 241 
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magnesium, and clinically significant phenomena are observed in the carriers of heterozygotic 242 
mutations of the ion channels TRPM6 and TRPM7 (transient receptor potential melastatin), which 243 
have a relevant role in the maintenance of magnesium homeostasis.17,19 Recently, Sakaguchi et al 244 
investigated 113,683 patients undergoing hemodialysis over a 2-year follow-up, finding an incidence 245 
of 2% for new hip fractures. The crude incidence rate was significantly higher among patients in the 246 
lower quartiles of serum magnesium levels (2.63%, 2.08%, 1.76%, and 1.49% in Q1–Q4, 247 
respectively). After adjustment for demographic and clinical factors, patients in Q1 had a 1.23-fold 248 
higher risk for hip fracture than those in Q4 (95% confidence interval, 1.06 to 1.44; P=0.01).20 Of 249 
course, given the fact that we did not dose magnesium levels in the DOPPS patients, these 250 
considerations, although biologically plausible, are purely speculative. 251 
Vitamin B12 deficiency has been associated with PPI use.21 Low vitamin B12 levels increase 252 
homocysteine levels, impairing cross-linking of bone collagen,22 and might increase the risk of bone 253 
fractures.23 In addition, peripheral neuropathy is also a consequence of vitamin B12 deficiency, 254 
increasing the risk of falls and, consequently, of bone fractures. The association between PPI use and 255 
increased risk of falls has been clearly demonstrated.24 Moreover, a direct PPI action on bone is also 256 
a possibility.25 Osteoclast function is dependent on proton pumps, which may be directly inhibited by 257 
PPIs, reducing bone resorption and turnover. This action was initially considered a potential treatment 258 
for osteoporosis,26 but altering bone turnover can deteriorate bone quality and increase the risk of 259 
fractures.  260 
PPI treatment has been associated with other relevant side effects, supporting the concept of 261 
significant adverse biologic effects on the body, besides the intended effects in the gastrointestinal 262 
system.27 Microbiome alterations with bacterial overgrowth may affect absorption of nutrients, 263 
including proteins and vitamin K, with potential long-term adverse effects on bone health and 264 
increased fracture risk.28 The potential interaction between PPIs and vitamin K is of interest, as 265 
vitamin K intake is associated with a protective effect on bone fractures.29  266 
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The large difference in the incidence rates of bone fractures among different countries, as well as the 267 
finding that in Italian and German patients the side effect of PPI was not visible, remain unexplained 268 
and they deserve further studies, in order to identify which factors might prevent bone fractures.   269 
Study strengths and limitations 270 
Strengths of our study are the large patient-population and the fact that the PPI-fractures 271 
relationship remains significant in Cox models including potential confounders and taking into 272 
account the competitive risk of death by the Fine and Gray approach10 as well as in multiple, cause-273 
specific hazards Cox models dealing patient death as a censoring event, stratifying by Country and 274 
study phase and matching patients of the two arms according to the prescription time-distribution. 275 
Furthermore, the potential distortion attributable to prevalent users’ bias on the study results was 276 
investigated by performing a detailed analysis in naïve patients versus no treated. Remarkably, such a 277 
sensitivity analysis provides results even more convincing than those obtained in the whole study 278 
population comparing prevalent + naïve PPI users versus no users. Lastly, the observational nature 279 
of our cohort represents another strength, rather than a weakness, of our study, because observational 280 
studies are recognized to be essential for investigating the safety profile of medications.30 Although 281 
in Cox models we adjusted for a series of well-known potential confounders (including demographic 282 
and clinical variables and bone biomarkers), the possibility that we did not adjust for ‘unmeasured 283 
confounders’ (including other tattribdrugs) cannot be excluded. However, the magnitude of the excess 284 
risk of bone and hip fractures (ranging from +22% to +62%) in PPI treated patients as compared to 285 
those untreated indicates that such a possibility is rather unlikely. Furthermore, it is important noting 286 
that the hazard ratio of PPI for bone fractures we found in our study (see Table 2) was very similar 287 
(1.22 versus 1.19) to that reported in a secondary analysis of the EVOLVE trial investigating the 288 
effect of Cinacalcet and other risk factors on the risk of bone fractures in dialysis patients.31 In this 289 
post-hoc analysis,31 in a multiple Cox model adjusting for a series of potential confounders, the effect 290 
of PPI on bone fractures did not achieve the formal statistical significance (P=0.09) most likely 291 
because of the low number of patients treated with PPI in the experimental EVOLVE trial (only 1141 292 
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patients versus 13283 patients in our real-life study). Our results are also in keeping with those 293 
reported in a recent case-control study by Vangala et al.32 in hemodialysis patients included in the 294 
USA Renal Data System. This study shows that the odds ratio of hip fractures is higher in PPI treated 295 
than in untreated patients, independently of a series of potential confounders. In the Vangala’s study, 296 
the adjusted excess risk of hip fractures of PPI use versus nonuse ranged from +16% to +21% 297 
(dependent on the frequency of PPI administration), figures lower than those found by us in primary 298 
(+35%) and sensitivity (+62% and +85%) analyses. This underestimation of the PPI effect on hip 299 
fractures may depend on the fact that Vangala et al.32 did not take into account the potential distortion 300 
due to prevalent users bias, did not include into multivariate models circulating levels of bone 301 
biomarkers and did not collect time to event data, all methodological issues which we specifically 302 
considered in our study, which also has the strength of including an international cohort of 303 
hemodialysis patients.  304 
Conclusions 305 
Considering the major health and economic burden of bone fractures, it is of utmost 306 
importance to adopt strategies for bone fractures prevention in a fragile population such as 307 
hemodialysis patients. The growing and convincing evidence of a harmful effect of PPI on bone 308 
health33-34, the internal coherence of the results emerged in our study as well as the magnitude of the 309 
negative effect of PPI use on the risk of bone and hip fractures in hemodialysis patients suggest 310 
caution and a careful evaluation of risks/benefits ratio while prescribing this class of drugs in this 311 
patient population. 312 
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Legends to figures 430 
 431 
Figure 1 Cumulative incidence of bone and hip fractures in PPI treated and untreated patients in the 432 
whole study cohort (upper panels) as well as in the sensitivity analysis (bottom panels) comparing 433 
naïve PPI users versus no users. See Methods-Statistical Analysis for more details. 434 
 435 
Supplementary Figure 1 Percentage of DOPPS patients on PPI treatment according to Countries.  436 
 437 
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Supplementary Figure 2 Country-stratified incidence rate of bone and hip fractures (and 95% CI) 438 
in PPI treated and untreated patients.  439 
440 
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Table 1 Demographic, clinical and biochemical characteristics of the whole cohort of patients and 441 
as divided according to PPI treatment. 442 
 443 
  PPI treatment 
  Whole  
cohort  
(n=27097) 
No  
users 
(n=13814) 
Prevalent users 
+ naive patients 
(n=13283) 
Age (years) 63.9±14.4 63.1±14.6 64.8±14 
BMI (kg/m2) 25.2±5.9 24.9±5.8 25.6±5.9 
Dialysis vintage (months) 24 (5-64) 23 (4-66) 24 (5-62) 
Male gender (%) 58.4% 59.7% 57.1% 
Caucasians (%)  68.6% 60.0% 77.5% 
African descent (%) 7.2% 8.1% 6.3% 
Asian/Indian (%) 20.1% 27.5% 12.4% 
Native American (%) 0.8% 0.72% 0.76% 
Other (%) 3.3% 3.6% 3.0% 
Smoking (%) 48.4% 46.8% 50.1% 
Background CV comorbidities       
Diabetics (%) 40.6% 39.0% 42.4% 
Coronary Artery Disease (%) 46.8% 43.4% 50.4% 
Chronic Heart Failure (%) 32.9% 30.6% 35.3% 
Cardiovascular Disease (%) 36.7% 34.5% 38.9% 
Cerebrovascular disease (%) 18.0% 16.4% 19.8% 
Peripheral Artery disease (%) 29.9% 26.0% 34.0% 
Biochemical data       
Albumin (g/dl) 3.7±0.4 3.7±0.4 3.6±0.5 
PTH (pg/ml) 199(104-340) 187(96-329) 209(114-349) 
Calcium (mg/dl) 9.1±0.7 9.1±0.7 9.0±0.6 
Phosphorus (mg/dl) 5.2±1.3 5.4±1.3 5.1±1.3 
Alkaline phosphatase (units/l) 109(77-185) 114(77-202) 106(77-170) 
**Kt/V 1.48±0.28 1.45±0.28 1.50±0.28 
Concomitant therapies*       
***Any Vitamin D (%) 65.2% 62.9% 67.5% 
Phosphate binders (%) 91.3% 92.1% 90.5% 
Calcium-based phosphate binders (%) 74.1% 77.7% 70.5% 
Data are mean ± SD, median and interquartile range, or as percent frequency, as appropriate. 444 
*Concomitant therapies when investigating the hip fractures are as follows:  445 
whole cohort, any Vitamin D: 65.4%; phosphate binders: 91.4%; calcium-based phosphate binders:74.3%. 446 
no users, any Vitamin D: 63.2%; phosphate binders: 92.2%; calcium-based phosphate binders:77.8%. 447 
prevalent users + naïve users, any Vitamin D: 67.7%; phosphate binders: 90.5%; calcium-based phosphate binders:70.6%. 448 
**Fractional urea clearance (a dimensionless index of dialysis adequacy).  449 
*** Includes either intravenous (alphacalcidol, paricalcitol, doxercalciferol, calcitriol, and other) or oral vitamin D. 450 
 451 
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Table 2 Multiple Cox regression analyses in all study sample (prevalent users + naive patients 
versus no users, n=27097) 
 
 Multiple Cox regression models taking into account the 
competing risk of death (Fine & Gray approach) 
Variables (units of increase) Bone fractures 
SHR (95% CI) and P value 
Hip fractures 
SHR (95% CI) and P value 
PPI treatment (0=no users; 1=prevalent users 
+ naïve users) 
1.22(1.10-1.36), P<0.001 1.35(1.13-1.62), P=0.001 
Age (1 year) 1.02(1.01-1.02), P<0.001 1.04(1.03-1.05), P<0.001 
Gender (0=F; 1=M) 0.64(0.57-0.71), P<0.001 0.68(0.58-0.83), P<0.001 
African descent (0=caucasians;1=yes) 0.61(0.47-0.79), P<0.001 0.72(0.46-1.11), P=0.13 
Asian/Indian (0= caucasians;1=yes) 0.89(0.77-1.04), P=0.15 0.41(0.29-0.56), P<0.001 
Native American (0= caucasians;1=yes) 1.07(0.62-1.85), P=0.80 1.66(0.74-3.72), P=0.22 
Other (0= caucasians;1=yes) 0.68(0.47-0.97), P=0.03 0.65(0.32-1.30), P=0.22 
BMI (kg/m2) 0.99(0.98-1.01), P=0.14 0.98(0.96-1.00), P=0.05 
Diabetes (0=no; 1=yes) 1.29(1.16-1.44), P<0.001 1.23(1.01-1.50), P=0.04 
Smoking (0=no; 1=yes) 1.09(0.98-1.23), P=0.12 1.10(0.90-1.34), P=0.34 
CV comorbidities (0=no; 1=yes) 1.03(0.91-1.17), P=0.66 1.21(0.95-1.56), P=0.13 
Dialysis vintage (years) 1.02(1.01-1.03), P<0.001 1.04(1.02-1.05), P<0.001 
Any Vitamin D (0=no; 1=yes) 0.87(0.78-0.97), P=0.01 0.94(0.78-1.14), P=0.54 
Phosphate binders (0=no; 1=yes) 0.91(0.77-1.08), P=0.27 0.88(0.67-1.17), P=0.38 
Albumin (1 g/dl) 0.73(0.65-0.83), P<0.001 0.62(0.50-0.77), P<0.001 
PTH (100 pg/ml) 1.01(1.00-1.03), P=0.05 1.02(0.99-1.04), P=0.15 
Calcium (1 mg/dl) 1.01(0.93-1.09), P=0.80 1.05(0.92-1.20), P=0.49 
Phosphate (1 mg/dl) 0.92(0.88-0.97), P=0.001 0.93(0.85-1.01), P=0.08 
Alkaline Phosphatase (1 unit/l) 1.01(1.00-1.02), P=0.006 1.00(0.99-1.01), P=0.23 
Kt/V (1 unit) 1.33(1.09-1.61), P=0.004 1.27(0.91-1.77), P=0.16 
Data are sub-hazard ratios (SHR), 95% CI and P value. 
Cox analyses including calcium-based phosphate binders instead of phosphate binders provided similar 
results (data not shown). 
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Table 3 Multiple Cox regression analyses in naïve PPI users versus no users (n=17090).  
 
 Multiple Cox regression models taking into account the 
competing risk of death (Fine & Gray approach) 
Variables (units of increase) Bone fractures 
SHR (95% CI) and P value 
Hip fractures 
SHR (95% CI) and P value 
PPI treatment (0=no users; 1=naïve  users) 1.29(1.10-1.51), P=0.002 1.62(1.24-2.11), P<0.001 
Age (1 year) 1.02(1.02-1.03), P<0.001 1.06(1.04-1.07), P<0.001 
Gender (0=F; 1=M) 0.56(0.49-0.65), P<0.001 0.56(0.43-0.73), P<0.001 
African descent (0=caucasians;1=yes) 0.49(0.35-0.70), P<0.001 0.74(0.43-1.28), P=0.28 
Asian/Indian (0= caucasians;1=yes) 0.79(0.66-0.95), P<0.001 0.34(0.23-0.51), P<0.001 
Native American (0= caucasians;1=yes) 1.41(0.74-2.68), P=0.30 2.78(1.14-6.79), P=0.03 
Other (0= caucasians;1=yes) 0.72(0.46-1.12), P=0.15 0.42(0.13-1.32), P=0.14 
BMI (1 kg/m2) 0.99(0.97-0.99), P=0.04 0.96(0.94-0.99), P=0.01 
Diabetes (0=no; 1=yes) 1.26(1.09-1.46), P=0.002 1.31(1.01-1.70), P=0.04 
Smoking (0=no; 1=yes) 1.13(0.96-1.32), P=0.15 1.05(0.80-1.38), P=0.74 
CV comorbidities (0=no; 1=yes) 1.05(0.89-1.23), P=0.58 1.24(0.89-1.73), P=0.20 
Dialysis vintage (years) 1.02(1.01-1.04), P<0.001 1.03(1.01-1.06), P=0.002 
Any Vitamin D (0=no; 1=yes) 0.92(0.80-1.07), P=0.28 1.19(0.91-1.54), PP=0.20 
Phosphate binders (0=no; 1=yes) 0.83(0.66-1.05), P=0.12 0.79(0.53-1.19), P=0.26 
Albumin (1 g/dl) 0.79(0.67-0.93), P=0.005 0.72(0.53-0.99), P=0.04 
PTH (100 pg/ml) 1.01(0.99-1.03), P=0.32 0.99(0.94-1.03), P=0.57 
Calcium (1 mg/dl) 0.95(0.86-1.05), P=0.34 1.01(0.84-1.23), P=0.88 
Phosphate (1 mg/dl) 0.92(0.86-0.97), P=0.005 0.94(0.85-1.06), P=0.30 
Alkaline Phosphatase (1 unit/l) 1.00(1.00-1.01), P=0.03 1.00(0.99-1.01), P=0.41 
Kt/V (1 unit) 1.24(0.95-1.61), P=0.11 0.97(0.60-1.57), P=0.90 
Data are sub-hazard ratios (SHR), 95% CI and P value. 
Cox analyses including calcium-based phosphate binders instead of phosphate binders provided similar 
results (data not shown). 
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Supplementary table I Demographic, clinical and biochemical characteristics of the whole cohort 
of patients and as divided according to PPI treatment (no users versus naïve users). 
 
 PPI treatment 
  No   
Users (n=13814) 
Naive patients 
PPI treated 
(n=3276) 
Age (years) 63.1±14.6 64.5±13.8 
BMI (kg/m2) 24.9±5.8 25.5 ±5.9 
Dialysis vintage (months) 23.5 (4-66) 24 (5.5-67) 
Male gender (%) 59.7% 57.7% 
Caucasians (%)  60.0% 69.1% 
African descent (%) 8.1% 7.7% 
Asian/Indian (%) 27.5% 19.0% 
Native American (%) 0.72% 0.79% 
Other (%) 3.6% 3.3% 
Diabetics (%) 39.0% 42.2% 
Smoking (%) 46.8% 49.2% 
Background CV comorbidities     
Coronary Artery Disease (%) 43.4% 48.5% 
Chronic Heart Failure (%) 30.6% 33.2% 
Cardiovascular Disease (%) 34.5% 35.3% 
Cerebrovascular disease (%) 16.4% 17.7% 
Peripheral Artery disease (%) 26.0% 31.2% 
Biochemical data     
Albumin (g/dl) 3.7±0.4) 3.6 ±0.4) 
PTH (pg/ml) 187 (96-329) 208(113-352) 
Calcium (mg/dl) 9.1±0.7 9.1±0.6 
Phosphorus(mg/dl) 5.4 ±1.3 5.2±1.2 
Alkaline phosphatase (units/l) 114 (77-202) 110 (79-195) 
Kt/V 1.45±0.28 1.50 ±0.29 
Concomitant therapies*      
Any Vitamin D (%) 62.9% 71.7% 
Phosphate binders (%) 92.1% 93.3% 
Calcium-based phosphate binders (%) 77.7% 74.8% 
Data are mean ± SD, median and interquartile range, or as percent frequency, as appropriate. 
*Concomitant therapies when investigating the hip fractures are as follows:  
no users, any Vitamin D: 63.2%; phosphate binders: 92.2%; calcium-based phosphate binders:77.8%. 
naïve users, any Vitamin D: 71.9%; phosphate binders: 93.4%; calcium-based phosphate binders:74.9%. 
 
 
 
